Lancet Psychiatry data show GLP-1 agonists cut AUD hospitalizations, with protection lasting 182 days post-discontinuation. Here's what that means...
A Lancet Psychiatry study links GLP-1 receptor agonists to fewer AUD and SUD hospitalizations—but the post-discontinuation signal demands a...
A Lancet Psychiatry study shows GLP-1 agonists cut AUD and SUD hospitalizations, but the protection fades after stopping —...
A Lancet RCT shows once-weekly semaglutide cut heavy drinking days in obese AUD patients — targeting a condition where...
A landmark Lancet RCT shows once-weekly semaglutide cuts alcohol use in obesity patients with AUD. The FDA's regulatory pathway...
A landmark Lancet RCT shows once-weekly semaglutide cut heavy drinking days in 108 AUD-plus-obesity patients. The FDA approval path...
